Document:

Amendment No. 1 to Common Stock Purchase Agreement

 Exhibit 10.37 
 AMENDMENT NO. 1 TO 
 COMMON STOCK PURCHASE AGREEMENT 

This AMENDMENT NO. 1 (the “First Amendment”) to that certain Common Stock Purchase Agreement, dated
November 11, 2009 (the “Agreement ”), by and between MAP Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Azimuth Opportunity Ltd., an international business company
incorporated under the laws of the British Virgin Islands (the “Investor”), is entered into as of 29 November, 2011 (the “First Amendment”). Capitalized terms not otherwise defined herein shall have
the meaning set forth in the Agreement. 
 RECITALS 

WHEREAS, Section 7.1 of the Agreement provides in part that, unless earlier terminated, the Agreement shall terminate
automatically on the earliest of (i) the first day of the month next following the 24-month anniversary of the Effective Date (the “Investment Period”), (ii) the date that the aggregate dollar amount of Shares registered under
the Registration Statement have been issued and sold and (iii) the date the Investor shall have purchased the Total Commitment of shares of Common Stock (subject in all cases to the Trading Market Limit); 

WHEREAS, the Agreement remains in full force and effect; 
 WHEREAS, Section 9.3 of the Agreement provides that the Agreement may be amended by a written instrument signed by the Company and the Investor; and 

WHEREAS, the Company and the Investor now desire to amend the Agreement as set forth herein. 

AGREEMENT 

NOW, THEREFORE, in consideration of the mutual promises, representations, warranties, covenants and conditions set forth in
the Agreement and this First Amendment, the receipt and sufficiency of which is hereby acknowledged, the parties hereto hereby agree as follows: 
 1. Amendment of Section 7.1. Effective as of the First Amendment Date, Section 7.1 of the Agreement shall be amended to replace the first sentence thereof with the
following: 
 “Unless earlier terminated as provided hereunder, this Agreement shall terminate automatically
on the earliest of (i) the first day of the month next following the 48-month anniversary of the Effective Date (the “Investment Period”), (ii) the date that the aggregate dollar amount of Shares registered under the Registration
Statement have been issued and sold and (iii) the date the Investor shall have purchased the Total Commitment of shares of Common Stock (subject in all cases to the Trading Market Limit).” 

2. Continuing Effect of Agreement. Except as expressly set forth in this First Amendment, all other provisions of
the Agreement remain in full force and effect. 
 3. Governing Law. This First Amendment shall be
governed by and construed in accordance with the internal procedure and substantive laws of the State of New York, without giving effect to the choice of law provisions of such state. 

4. Counterparts. This First Amendment may be executed in counterparts, all of which taken together shall
constitute one and the same original and binding instrument and shall become effective when all counterparts have been signed by each party and delivered to the other parties hereto, it being understood that all parties hereto need not sign the same
counterpart. 
 IN WITNESS WHEREOF, the parties hereto have caused this AMENDMENT NO. 1 TO THE AGREEMENT to
be executed and delivered as of the First Amendment Date. 
  

			
	Company: MAP Pharmaceuticals, Inc.	  	Investor: AZIMUTH OPPORTUNITY LTD
		
	 /s/ Timothy S. Nelson
	  	 /s/ Deirdre M. McCoy

	By: Timothy S. Nelson	  	By: Deirdre M. McCoy
	 Title: President and Chief Executive Officer
	  	 Title: Corporate SecretaryFirst Amendment to Change in Control Agreement

 Exhibit 10.38 
 EXECUTION COPY 
 FIRST
AMENDMENT TO CHANGE IN CONTROL AGREEMENT 
 This First Amendment to the Change in Control Agreement, dated
February 1, 2012, is entered into by and between MAP Pharmaceuticals, Inc., a Delaware corporation (“Company”), and Timothy S. Nelson (“Executive”). 

WHEREAS, Executive and the Company entered into that certain Change in Control Agreement effective September 18,
2007 (the “Change in Control Agreement”); 
 WHEREAS, Executive and the Company have mutually
agreed that it is in their best interest to amend the Change in Control Agreement pursuant to the terms set forth herein. 
 NOW, THEREFORE, in consideration of the mutual covenants herein contained and other good and valuable consideration, receipt of which is hereby acknowledged, the parties hereto do hereby agree that,
effective as of the date hereof, the Change in Control Agreement is hereby amended as follows; 

1.     Effective as of the date hereof, Subsection (iv) of the definition of “Good Reason”
contained in Section 1(d) of the Change in Control Agreement shall be replaced and amended to read in its entirety as follows: 
 (iv) the assignment to Executive of any duties or responsibilities that results in any diminution or adverse change of Executive’s position, status, circumstances of employment or scope of
responsibilities; 
 2.     Except as hereby specifically amended or modified, the terms of the Change
in Control Agreement, as amended by this First Amendment, shall remain in full force and effect. This First Amendment may be executed by the parties hereto in two counterparts, each of which shall be an original and all of which together shall
constitute one and the same agreement. This First Amendment shall be governed in all respects by the laws of the State of California, without regard to the principles conflicts of laws. 

[signature page follows] 

 IN WITNESS WHEREOF, the parties hereto have executed and delivered this
First Amendment to the Change in Control Agreement as of the day and year first above written. 
  

	
	
	EXECUTIVE
	
	/s/ Timothy S. Nelson        
	Timothy S. Nelson

  

					
	MAP PHARMACEUTICALS, INC.
		
	BY:	 	/s/ C. Friedman        
		 	NAME:	 	C. Friedman
		 	TITLE:	 	SVP, General Counsel and Secretary

  
 2First Amendment to Change in Control Agreement

 Exhibit 10.39 
 EXECUTION COPY 
 FIRST AMENDMENT TO CHANGE
IN CONTROL AGREEMENT 
 This First Amendment to the Change in Control Agreement, dated February 6,
2012, is entered into by and between MAP Pharmaceuticals, Inc., a Delaware corporation (“Company”), and Thomas A. Armer, Ph.D (“Executive”). 

WHEREAS, Executive and the Company entered into that certain Change in Control Agreement effective September 12,
2007 (the “Change in Control Agreement”); 
 WHEREAS, Executive and the Company have mutually
agreed that it is in their best interest to amend the Change in Control Agreement pursuant to the terms set forth herein. 
 NOW, THEREFORE, in consideration of the mutual covenants herein contained and other good and valuable consideration, receipt of which is hereby acknowledged, the parties hereto do hereby agree that,
effective as of the date hereof, the Change in Control Agreement is hereby amended as follows: 

1.      Effective as of the date hereof, Subsection (iv) of the definition of “Good Reason”
contained in Section 1(d) of the Change in Control Agreement shall be replaced and amended to read in its entirety as follows: 
 (iv) the assignment to Executive of any duties or responsibilities that results in any diminution or adverse change of Executive’s position, status, circumstances of employment or scope of
responsibilities; 
 2.      Except as hereby specifically amended or modified, the terms of the Change
in Control Agreement, as amended by this First Amendment, shall remain in full force and effect. This First Amendment may be executed by the parties hereto in two counterparts, each of which shall be an original and all of which together shall
constitute one and the same agreement. This First Amendment shall be governed in all respects by the laws of the State of California, without regard to the principles conflicts of laws. 

[signature page follows] 

 IN WITNESS WHEREOF, the parties hereto have executed and delivered this
First Amendment to the Change in Control Agreement as of the day and year first above written. 
  

	
	
	EXECUTIVE
	
	 /s/ Thomas A. Armer

	Thomas A. Armer, Ph.D

  

					
	MAP PHARMACEUTICALS, INC.
		
	BY:	 	/s/ Timothy S. Nelson
		 	NAME:	 	Timothy S. Nelson
		 	TITLE:	 	President and CEO

  
 2First Amendment to Severance Agreement

 Exhibit 10.40 
 EXECUTION COPY 
 FIRST AMENDMENT TO
SEVERANCE AGREEMENT 
 This First Amendment to the Severance Agreement, dated February 1, 2012, is
entered into by and between MAP Pharmaceuticals, Inc., a Delaware corporation (“Company”), and Timothy S. Nelson (“Executive”). 

WHEREAS, Executive and the Company entered into that certain Severance Agreement effective March 19, 2009 (the
“Severance Agreement”); 
 WHEREAS, Executive and the Company have mutually agreed that it is
in their best interest to amend the Severance Agreement pursuant to the terms set forth herein. 
 NOW,
THEREFORE, in consideration of the mutual covenants herein contained and other good and valuable consideration, receipt of which is hereby acknowledged, the parties hereto do hereby agree that, effective as of the date hereof, the Severance
Agreement is hereby amended as follows: 
 1.     Effective as of the date hereof, Subsection (iv) of
the definition of “Good Reason” contained in Section 1(d) of the Severance Agreement shall be replaced and amended to read in its entirety as follows; 

(iv) the assignment to Executive of any duties or responsibilities that results in any diminution or adverse change of
Executive’s position, status, circumstances of employment or scope of responsibilities; 
 2.    
Except as hereby specifically amended or modified, the terms of the Severance Agreement, as amended by this First Amendment, shall remain in full force and effect. This First Amendment may be executed by the parties hereto in two counterparts, each
of which shall be an original and all of which together shall constitute one and the same agreement. This First Amendment shall be governed in all respects by the laws of the State of California, without regard to the principles conflicts of laws.

 [signature page follows] 

 IN WITNESS WHEREOF, the parties hereto have executed and delivered this
First Amendment to the Severance Agreement as of the day and year first above written. 
  

	
	
	EXECUTIVE
	
	/s/ Timothy S.Nelson        
	Timothy S.Nelson

  

					
	MAP PHARMACEUTICALS, INC.
		
	BY:	 	/s/ C. Friedman        
		 	NAME:	 	C. Friedman
		 	TITLE:	 	SVP, General Counsel and Secretary

  
 2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00202-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00202-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00202-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00202-of-00352.parquet"}]]